Trevi Therapeutics Stock Current Valuation
| TRVI Stock | USD 4.36 0.24 5.83% |
Valuation analysis of Trevi Therapeutics helps investors to measure Trevi Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -2.84. The current Enterprise Value Multiple is estimated to decrease to -2.84. Fundamental drivers impacting Trevi Therapeutics' valuation include:
Undervalued
Today
Please note that Trevi Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Trevi Therapeutics is based on 3 months time horizon. Increasing Trevi Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Trevi Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Trevi Stock. However, Trevi Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.36 | Real 5.31 | Target 7.33 | Hype 4.31 |
The intrinsic value of Trevi Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Trevi Therapeutics' stock price.
Estimating the potential upside or downside of Trevi Therapeutics helps investors to forecast how Trevi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Trevi Therapeutics more accurately as focusing exclusively on Trevi Therapeutics' fundamentals will not take into account other important factors: Trevi Therapeutics Company Current Valuation Analysis
Trevi Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Trevi Therapeutics Current Valuation | 303.81 M |
Most of Trevi Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trevi Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as Current Valuation. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Trevi Therapeutics has a Current Valuation of 303.81 M. This is 97.88% lower than that of the Pharmaceuticals sector and 93.46% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.17% higher than that of the company.
Trevi Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.Trevi Therapeutics is currently under evaluation in current valuation category among its peers.
Trevi Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 43.7M | 17.9M | 124.6M | 132.7M | 119.4M | 63.2M | |
| Enterprise Value | 12.9M | (4.3M) | 121.2M | 101.6M | 116.9M | 64.4M |
Trevi Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Trevi Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 303.81 M | ||||
| Shares Outstanding | 89.37 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 70.42 % | ||||
| Number Of Shares Shorted | 4.66 M | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.34 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 5.18 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (31.71 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 9.81 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 368.19 M | ||||
| Total Asset | 89.4 M | ||||
| Retained Earnings | (239.13 M) | ||||
| Working Capital | 81.72 M | ||||
| Net Asset |